CJC-1295 vs Sermorelin

How do they actually differ?

Evidence tier: 2 — sermorelin has FDA-approval-grade pediatric data plus pharmacology-anchored adult studies (Walker 1998-era literature reviewed in Prakash 2002); CJC-1295 with DAC anchored by Teichman 2006 dose-escalation study.

Sermorelin and CJC-1295 are both growth-hormone-releasing-hormone (GHRH) analogs that act on the GHRH receptor of the anterior pituitary somatotrophs to drive endogenous growth hormone release. They are not GH itself — they are upstream secretagogues. The structural difference is small but pharmacokinetically decisive. Sermorelin is a 29-amino-acid peptide corresponding to the biologically active fragment of native human GHRH(1-44). It binds the GHRH receptor with high affinity, triggers a normal GH pulse, and is then cleared rapidly by serum dipeptidyl peptidase IV (DPP-IV) — the functional half-life is approximately 10 minutes. The result is a tight, physiologic GH pulse that mirrors endogenous nocturnal release patterns. CJC-1295 is a modified 30-amino-acid sermorelin derivative engineered with a Drug Affinity Complex (DAC) — a maleimidopropionic acid moiety that covalently binds circulating albumin. Albumin binding extends half-life to approximately 6-8 days, producing chronic GHRH receptor stimulation rather than discrete pulses. Mean serum GH and IGF-1 elevations persist for over a week per injection. The trade-off is loss of pulsatility — endogenous GH biology is pulse-based, with peak amplitude and inter-pulse trough rhythm carrying signaling information that sustained elevation flattens. Sermorelin preserves the pulse architecture; CJC-1295 with DAC sacrifices it for dosing convenience.

Who should choose sermorelin?

Evidence tier: 2 — FDA approval data in pediatric idiopathic GH deficiency; multiple adult studies in age-related GH decline (Walker era).

Sermorelin is the better fit for users prioritizing physiologic GH biology — age-related GH decline ("somatopause") in adults 40+ wanting to stimulate the body's own GH pulse architecture rather than impose external GH exposure. The peptide's pulsatile pattern preserves the negative-feedback loops that keep IGF-1 within physiologic range, reducing the theoretical cancer-promotion concern that has shadowed exogenous recombinant GH for decades. Sermorelin is also the right choice for patients who want the most-evidenced GHRH analog on an FDA-approval basis (the Geref product, FDA-approved in 1990 for diagnostic use and 1997 for pediatric idiopathic GH deficiency, was withdrawn from commercial production in 2008 due to manufacturing economics, not safety). Compounded sermorelin remains widely available through 503A pharmacies. The dosing pattern — 100-300 mcg subcutaneously before bed, daily — aligns with the natural nocturnal GH peak and is the canonical age-management protocol. Stacking with ipamorelin (a GHRP-class secretagogue) is the standard amplification pattern. Daily injection is the trade-off; users with needle aversion or low compliance may prefer CJC-1295's weekly dosing convenience. Sermorelin should not be used by athletes subject to WADA testing — it is on the prohibited list as S2. Discuss any GH-axis intervention with your endocrinologist.

Who should choose CJC-1295?

Evidence tier: 3 — Teichman 2006 multi-center RCT in healthy adults documents safety and pharmacokinetics; community use widespread in age-management practice.

CJC-1295 (with DAC) fits users prioritizing dosing convenience and steady-state GH elevation over physiologic pulse fidelity. The 1-2 mg subcutaneous injection once or twice weekly is substantially lower compliance burden than daily sermorelin — a real-world advantage for busy users. The peptide is well-suited to body-composition-focused protocols where sustained GH and IGF-1 elevation may produce more visible recomposition signal than pulsatile sermorelin in shorter (6-12 week) cycles, though direct head-to-head comparison data does not exist. The "without DAC" form (sometimes called Modified GRF 1-29 or CJC-1295 No-DAC) lacks the albumin-binding moiety, behaves pharmacokinetically more like sermorelin, and is dosed daily — that variant defeats the convenience argument for CJC-1295 and largely redundifies with sermorelin. CJC-1295 with DAC is the version that produces the meaningful dosing-frequency differential. Stacking with ipamorelin is less useful here than with sermorelin because CJC-1295 already produces sustained receptor activation; combination with a GHRP class agent risks excessive GH elevation. CJC-1295 has never been FDA-approved at any indication or in any country — it is research-tier and compounded-only in the United States. WADA classifies it as prohibited (S2) like sermorelin. Discuss any GH-axis intervention with your endocrinologist; do not use either peptide without clinical supervision.

What does the evidence base actually say?

Evidence tier: 2 — sermorelin has FDA-approval-grade pediatric data; CJC-1295 has Teichman 2006 RCT and limited follow-up; no head-to-head trial exists.

Sermorelin's evidence base is older and deeper. The FDA approval pathway in pediatric idiopathic GH deficiency was supported by multi-trial data showing GH pulse stimulation, IGF-1 elevation, and growth response in prepubertal children with documented deficiency. Adult studies in age-related GH decline (the so-called "Walker era" of GHRH analog research in the 1990s) demonstrated that sermorelin restores GH-IGF-1 axis function in older adults with reduced amplitude pulse patterns. The pediatric data was sufficient for FDA approval; the adult age-management data was sufficient for off-label clinical practice. CJC-1295's clinical evidence rests primarily on Teichman 2006 (J Clin Endocrinol Metab) — a multi-center, randomized, placebo-controlled, dose-escalation study in healthy adults documenting that single subcutaneous injections produced 2-10x mean GH elevation for 6+ days and 1.5-3x mean IGF-1 elevation for 9-11 days, with calculated half-life 5.8-8.1 days. The companion Teichman 2006 paper documented that pulsatile GH secretion partially persists during continuous CJC-1295 stimulation, somewhat softening the "lost pulsatility" critique. There is no head-to-head sermorelin-versus-CJC-1295 RCT in any indication; the comparison rests on pharmacokinetic profile and pulse-versus-sustained-exposure mechanism inference. There are no long-term (12+ month) cancer-safety registries for either peptide outside the pediatric sermorelin approval data.

Cost, access, and regulatory comparison

Evidence tier: 2 — pricing reflects April 2026 compounded retail; FDA category status current.

Sermorelin (Geref, originally Serono) was FDA-approved in 1990 (diagnostic) and 1997 (pediatric idiopathic GH deficiency) but withdrawn from commercial production in 2008 due to manufacturing economics — not safety. Compounded sermorelin remains widely available through 503A pharmacies for off-label adult use; insurance coverage is rare. Compounded retail runs $120-220 per month at typical 100-300 mcg nightly dosing. CJC-1295 has never been FDA-approved at any indication. It is compounded-only in the United States through 503A pharmacies, with retail running $180-320 per month at typical 1-2 mg weekly dosing. Both peptides remain on the WADA prohibited list as S2 (peptide hormones, growth factors, related substances and mimetics) and trigger anti-doping violations in tested sport. Neither is currently a target of immediate FDA enforcement action, but the broader compounded-peptide regulatory direction is uncertain — the FDA's PCAC review process has been actively reclassifying compounded peptides, and either or both could move category status. See the FDA Bulks list for 503A compounding for current category status and the FDA Geref discontinuation history for sermorelin's regulatory record.

Related on Peptide Story

• CJC-1295 / Ipamorelin fact box
• Sermorelin fact box
• GLP-1 muscle preservation with Tesamorelin

References

• Teichman SL, Neale A, Lawrence B, et al. 2006. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PMID 16352683
• Ionescu M, Frohman LA. 2006. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. PMID 17018654
• Prakash A, Goa KL. 1999. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. PMID 18031173
• Walker RF. 2006. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. PMC2699646